Overview

A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication
Phase:
Phase 4
Details
Lead Sponsor:
Bracco Diagnostics, Inc